ODOMZO
Total Payments
$2.9M
Transactions
1,811
Doctors
1,131
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $4,875 | 1 | 0 |
| 2020 | $213,743 | 731 | 525 |
| 2019 | $236,147 | 1,023 | 727 |
| 2018 | $113,522 | 15 | 1 |
| 2017 | $2.3M | 41 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.5M | 62 | 87.7% |
| Honoraria | $276,849 | 88 | 9.6% |
| Food and Beverage | $42,009 | 1,550 | 1.5% |
| Travel and Lodging | $23,039 | 104 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,946 | 4 | 0.3% |
| Consulting Fee | $3,584 | 1 | 0.1% |
| Education | $137.48 | 2 | 0.0% |
Payments by Type
Research
$2.5M
62 transactions
General
$354,564
1,749 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE II RANDOMIZED DOUBLE BLIND STUDY OF EFFICACY AND SAFETY OF TWO DOSE LEVELS OF LDE225 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BASAL CELL CARCINOMA | Novartis Pharmaceuticals Corporation | $591,849 | 0 |
| PHASE 2 TRIAL OF LDE225 AND LENALIDOMIDE MAINTENANCE POST AUTOLOGOUS STEM CELL TRANSPLANT FOR MULTIPLE MYELOMA | Novartis Pharmaceuticals Corporation | $330,320 | 0 |
| PHASE 1 STUDY STUDY OF 5 AZACYTIDINE AND HEDGEHOG PATHWAY INHIBITION IN MYELOID MALIGNANCIES | Novartis Pharmaceuticals Corporation | $310,629 | 0 |
| A PHASE IB AND OR II TRIAL OF THE HEDGEHOG INHIBITOR LDE225 WITH ETOPOSIDE AND CISPLATIN IN THE FIRST LINE TREATMENT OF PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER ES SCLC | Novartis Pharmaceuticals Corporation | $281,680 | 0 |
| A PHASE IB MULTI CENTER TWO PARALLEL GROUP OPEN LABEL DRUG DRUG INTERACTION STUDY TO ASSESS THE EFFECT OF LDE225 ON THE PHARMACOKINETICS OF BUPROPION AND WARFARIN IN PATIENTS WITH ADVANCED SOLID TUMORS | Novartis Pharmaceuticals Corporation | $262,495 | 0 |
| A PHASE 1B CLINICAL TRIAL OF LDE225 IN COMBINATION WITH FLUOROURACIL LEUCOVORIN OXALIPLATIN AND IRINOTECAN FOLFIRINOX IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA WITH AN EXPANSION COHORT AT THE RECOMMENDED PHASE 2 DOSE | Novartis Pharmaceuticals Corporation | $242,872 | 0 |
| DUAL PATHWAY INHIBITION AS SECOND LINE THERAPY OF PATIENTS WITH NUCLEAR GLI1 ENRICHED ADVANCED GASTROESOPHAGEAL ADENOCARCINOMA | Novartis Pharmaceuticals Corporation | $191,432 | 0 |
| PHASE I STUDY OF SINGLE AGENT LDE225 AS SECOND LINE THERAPY IN PATIENTS WITH ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA AND CHILD PUGH A CIRRHOSIS | Novartis Pharmaceuticals Corporation | $163,282 | 0 |
| PHASE IB AND OR II TRIAL OF LDE225 AND WEEKLY PACLITAXEL IN RECURRENT PLATINUM RESISTANT OVARIAN ADENOCARCINOMA | Novartis Pharmaceuticals Corporation | $35,740 | 0 |
| A PHASE 1B MULTI CENTER OPEN LABEL DOSE ESCALATION STUDY OF ORAL LDE225 IN COMBINATION WITH BKM120 IN PATIENTS WITH ADVANCED SOLID TUMORS | Novartis Pharmaceuticals Corporation | $34,630 | 0 |
| A DOUBLE BLIND RANDOMIZED OPEN LABEL TWO ARM PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF COMBINATION LDE225 AND BKM120 FOR THE TREATMENT OF ADVANCED BASAL CELL CARCINOMAS | Novartis Pharmaceuticals Corporation | $29,861 | 0 |
| A PHASE 1 STUDY OF LDE225 IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY MEDULLOBLASTOMA OR OTHER TUMORS POTENTIALLY DEPENDENT ON THE HEDGEHOG SIGNALING PATHWAY | Novartis Pharmaceuticals Corporation | $24,358 | 0 |
| A PHARMACODYNAMIC PRESURGICAL STUDY OF HEDGEHOG PATHWAY INHIBITION WITH LDE225 IN MEN WITH HIGH RISK LOCALIZED PROSTATE CANCER | Novartis Pharmaceuticals Corporation | $21,947 | 0 |
| PHASE I TRIAL OF LDE225 FOR STEROID REFRACTORY CHRONIC GVHD | Novartis Pharmaceuticals Corporation | $12,696 | 0 |
| A PHASE IB AND OR II OPEN LABEL MULTI CENTER DOSE FINDING STUDYTO ASSESS THE SAFETY AND EFFICACY OF THE ORAL COMBINATION OF LDE225 AND INC424 RUXOLITINIB IN PATIENTS WITHMYELOFIBROSIS | Novartis Pharmaceuticals Corporation | $1,050 | 0 |
| A PHASE III MULTI CENTER OPEN LABEL RANDOMIZED CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ORAL LDE225 VERSUS TEMOZOLOMIDE IN PATIENTS WITH HH PATHWAY ACTIVATED RELAPSED MEDULLOBLASTOMA | Novartis Pharmaceuticals Corporation | $765.00 | 0 |
| PHASE I TRIAL OF LDE225 WITH SQ BORTEZOMIB IN PATIENTS WITH RELAPSED OR RELAPSED AND OR REFRACTORY MULTIPLE MYELOMA | Novartis Pharmaceuticals Corporation | $545.00 | 0 |
| A PHASE I MULTICENTER OPEN LABEL DOSE ESCALATION STUDY OF ORAL LDE225 IN PATIENTS WITH ADVANCED SOLID TUMORS | Novartis Pharmaceuticals Corporation | $532.00 | 0 |
Top Doctors Receiving Payments for ODOMZO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $2.5M | 62 |
| , MD | Surgical Oncology | Tampa, FL | $63,426 | 70 |
| , M.D | Dermatology | Philadelphia, PA | $25,772 | 37 |
| , MD, PHD, MPH | Hematology & Oncology | Beverly Hills, CA | $24,434 | 19 |
| , MD | Dermatology | Lousiville, KY | $17,550 | 14 |
| , M.D | Procedural Dermatology | Brooklyn, NY | $16,193 | 21 |
| , MD | Dermatology | Largo, FL | $13,725 | 18 |
| , M.D | Dermatology | Smithtown, NY | $12,801 | 11 |
| , MD | Dermatology | Delray Beach, FL | $10,429 | 16 |
| , D.O | Dermatology | Springfield, OH | $9,336 | 12 |
| , D.D.S | General Practice | North Manchester, IN | $8,141 | 9 |
| , MD | Dermatology | West Harrison, NY | $7,875 | 4 |
| , M.D | MOHS-Micrographic Surgery | North Little Rock, AR | $7,191 | 5 |
| , DO | Dermatology | Marion, OH | $6,618 | 4 |
| , M.D | Dermatology | Corbin, KY | $6,229 | 11 |
| , MD | Dermatology | West Chester, OH | $6,028 | 10 |
| , MD | MOHS-Micrographic Surgery | Nashville, TN | $5,854 | 5 |
| , MD PHD | Dermatology | Calhoun, GA | $5,379 | 11 |
| , M.D, | Dermatology | Philadelphia, PA | $5,378 | 10 |
| , M.D | Dermatology | New York, NY | $5,352 | 9 |
| , MD | Medical Oncology | Salina, KS | $5,336 | 8 |
| , MD | Hospice and Palliative Medicine | Fort Myers, FL | $5,239 | 9 |
| , M.D | Dermatology | Charleston, SC | $4,944 | 3 |
| , MD | MOHS-Micrographic Surgery | Carmel, IN | $4,815 | 3 |
| , MD | Dermatology | Ormond Beach, FL | $4,149 | 2 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $2.5M
- Sun Pharmaceutical Industries Inc. $340,221
- DUSA Pharmaceuticals, Inc. $10,760
Product Information
- Type Drug
- Total Payments $2.9M
- Total Doctors 1,131
- Transactions 1,811
About ODOMZO
ODOMZO is a drug associated with $2.9M in payments to 1,131 healthcare providers, recorded across 1,811 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2021. In 2021, $4,875 was paid across 1 transactions to 0 doctors.
The most common payment nature for ODOMZO is "Unspecified" ($2.5M, 87.7% of total).
ODOMZO is associated with 18 research studies, including "A PHASE II RANDOMIZED DOUBLE BLIND STUDY OF EFFICACY AND SAFETY OF TWO DOSE LEVELS OF LDE225 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BASAL CELL CARCINOMA" ($591,849).